Read the latest press releases from 10xBio.
10xBio Announces the Completion of Phase 1B Clinical Trial of 10XB101
SAN DIEGO (May 6, 2019) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has completed a Phase 1B study of its novel injectable drug product for body contouring. The company’s drug product 10XB101 is a novel formulation of polidocanol which is approved in the U.S….
10xBio Completes Series A Financing
SAN DIEGO (April 2, 2018) – 10xBio, LLC, a privately-held biotechnology company, completed a Series A financing from a select group of partners and private investors during the first quarter of 2018. Capital raised totaled $2,660,000 including conversion of outstanding notes. Proceeds will be used to advance the company’s lead asset, 10XB101…
10xBio Announces the Acceptance of a U.S. IND for the Initiation of Clinical Trials of 10XB101
SAN DIEGO (April 2, 2018) – 10xBio, LLC, a privately-held biotechnology company, announced today that the Investigational New Drug “IND” application for 10XB101 has been accepted by the U.S. FDA.
10xBio Announces Issuance of U.S. Patent
SAN DIEGO (May 31, 2017) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has been issued patent 9,351,945 from the U.S. Patent and Trademark Office.